Home >> Research Area >>Tyrosine Kinase/Adaptors>>PDGFR>> Crenolanib (CP-868596)

Crenolanib (CP-868596)

PDGFR-β inhibitor,potent and selective CAS# 670220-88-9

Crenolanib (CP-868596)

Catalog No. BCC3671----Order now to get a substantial discount!

Product Name & Size Price Stock
Crenolanib (CP-868596): 5mg $69 In Stock
Crenolanib (CP-868596): 10mg Please Inquire In Stock
Crenolanib (CP-868596): 20mg Please Inquire Please Inquire
Crenolanib (CP-868596): 50mg Please Inquire Please Inquire
Crenolanib (CP-868596): 100mg Please Inquire Please Inquire
Crenolanib (CP-868596): 200mg Please Inquire Please Inquire
Crenolanib (CP-868596): 500mg Please Inquire Please Inquire
Crenolanib (CP-868596): 1000mg Please Inquire Please Inquire
Related Products

Quality Control of Crenolanib (CP-868596)

Number of papers citing our products

Chemical structure

Crenolanib (CP-868596)

3D structure

Chemical Properties of Crenolanib (CP-868596)

Cas No. 670220-88-9 SDF Download SDF
PubChem ID 10366136 Appearance Powder
Formula C26H29N5O2 M.Wt 443.54
Type of Compound N/A Storage Desiccate at -20°C
Synonyms CP-868596
Solubility DMSO : 33.33 mg/mL (75.15 mM; Need ultrasonic)
Chemical Name 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine
SMILES CC1(COC1)COC2=CC3=C(C=C2)N(C=N3)C4=NC5=C(C=CC=C5N6CCC(CC6)N)C=C4
Standard InChIKey DYNHJHQFHQTFTP-UHFFFAOYSA-N
Standard InChI InChI=1S/C26H29N5O2/c1-26(14-32-15-26)16-33-20-6-7-22-21(13-20)28-17-31(22)24-8-5-18-3-2-4-23(25(18)29-24)30-11-9-19(27)10-12-30/h2-8,13,17,19H,9-12,14-16,27H2,1H3
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of Crenolanib (CP-868596)

DescriptionCrenolanib (CP-868596) is a potent and selective inhibitor of PDGFRα/β with Kd of 2.1 nM/3.2 nM.
TargetsPDGFRαPDGFRβ    
IC502.1 nM (Kd)3.2 nM (Kd)    

Protocol

Cell Assay [2]
Viable cell numbers following drug treatment are measured using the WST-1 assay. Briefly, 1×103 cells are seeded in 100 μL complete medium per well in 96-well tissue culture plates and incubated with crenolanib (0-10 μM) at 37°C in 5% CO2 for 96 h. 10 μL WST-1 reagent is then added to each well, incubation is continued for two additional hours and the color developed is quantified according to the manufacturer’s instructions. Each experiment is performed in triplicate. IC50 concentrations are calculated by the least square fit of dose–response inhibition in a non-linear regression model using GraphPad Prism V software.

Animal Administration [3]
A549 cells are injected into the axillary regions of mice (2×106 cells/mouse). When the tumor volumes reached 70 mm3, the mice are randomLy allocated to the control group, low-dose crenolanib group (10 mg/kg), or high-dose crenolanib group (20 mg/kg) (n=6 per group). The vehicle for crenolanib treatment consists of 10% 1-methyl-2-pyrrolidinone and 90% polyethylene glycol 300. The tumor size and mouse body weight are measured every other day for about 2 weeks. The tumor volume is calculated as follows: (mm3)=(width×width×length)/2. After treatment, the mice are euthanized using carbon dioxide, and the tumors are harvested and analyzed.

References:
[1]. Heinrich MC, et al.Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors. Clin Cancer Res, 2012, Jun 27. [2]. Mathias TJ, et al. The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant concentrations. Invest New Drugs. 2015 Apr;33(2):300-9. [3]. Wang P, et al. Crenolanib, a PDGFR inhibitor, suppresses lung cancer cell proliferation and inhibits tumor growth in vivo. Onco Targets Ther. 2014 Sep 26;7:1761-8.

Crenolanib (CP-868596) Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Crenolanib (CP-868596) Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Crenolanib (CP-868596)

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.2546 mL 11.2729 mL 22.5459 mL 45.0918 mL 56.3647 mL
5 mM 0.4509 mL 2.2546 mL 4.5092 mL 9.0184 mL 11.2729 mL
10 mM 0.2255 mL 1.1273 mL 2.2546 mL 4.5092 mL 5.6365 mL
50 mM 0.0451 mL 0.2255 mL 0.4509 mL 0.9018 mL 1.1273 mL
100 mM 0.0225 mL 0.1127 mL 0.2255 mL 0.4509 mL 0.5636 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on Crenolanib (CP-868596)

Crenolanib (CP-868596) is a potent, specific, and orally available inhibitor of PDGFRα, PDGFRβ and FLT3 with inhibitor-binding constant (Kd) of 3.2, 2.1, and 0.74 nM, respectively [1].

It has been shown that crenolanib is more potent than quizartinib and sorafenib at blocking FLT3 autophosphorylation and causing cytotoxicity [2]. Crenolanib is confirmed to be100-fold more potent than imatinib at suppressing D842V mutation. In addition, it has been reported that crenolanib inhibits PDGFRα D842V mutation rather than V561D mutation, with IC50 value of 10 nM [1]. In EOL-1 cells, crenolanib also inhibits the FIP1L1-PDGFRA fusion kinase activity (IC50=1 nM) and cell proliferation (IC50= 0.2 pM)[1].

References:
[1] Heinrich MC1, Griffith D, McKinley A, Patterson J, Presnell A, Ramachandran A, Debiec-Rychter M.

Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors. Clin Cancer Res. 2012 Aug 15;18(16):4375-84.

[2] Galanis A1, Ma H, Rajkhowa T, Ramachandran A, Small D, Cortes J, Levis M. Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants. Blood. 2014 Jan 2;123(1):94-100.

Featured Products
New Products
 

Description

Crenolanib is a potent and selective inhibitor of wild-type and mutant isoforms of the class III receptor tyrosine kinases FLT3 and PDGFRα/β with Kds of 0.74 nM and 2.1 nM/3.2 nM, respectively.

Keywords:

Crenolanib (CP-868596),670220-88-9,CP-868596,Natural Products,PDGFR, buy Crenolanib (CP-868596) , Crenolanib (CP-868596) supplier , purchase Crenolanib (CP-868596) , Crenolanib (CP-868596) cost , Crenolanib (CP-868596) manufacturer , order Crenolanib (CP-868596) , high purity Crenolanib (CP-868596)

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: